IMMUTEP Ltd is an Australian development-stage biopharmaceutical company focused on immunotherapeutic products for cancer and autoimmune diseases, all related to LAG-3 (lymphocyte activation gene 3). Its five programs include eftilagimod alfa (efti/IMP321), IMP701 (ieramilimab), IMP731, IMP761, and an early-stage anti-LAG-3 small molecule. Efti, its most advanced candidate, is being evaluated in Phase II and Phase III trials in combination with pembrolizumab (MSD) and avelumab (Merck KGaA/Pfizer). The company also sells LAG-3 research reagents.
664 total filings indexed. 664 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001506184 |
| Ticker | IMMP |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | C3 |
| Website | https://www.immutep.com |
| Listed | 1988-01-01 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/IMMP (~200 tokens, structured JSON with cryptographic provenance)